⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNDX News
Syndax Pharmaceuticals, Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX
prnewswire.com
SNDX
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
globenewswire.com
SNDX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc. - SNDX
accessnewswire.com
SNDX
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law
businesswire.com
SNDX
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
globenewswire.com
SNDX
SNDX SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates Syndax Pharmaceuticals, Inc. for Possible Securities Law Violations
accessnewswire.com
SNDX
Syndax Pharmaceuticals, Inc. (SNDX) Securities Fraud Investigation - Levi & Korsinsky
accessnewswire.com
SNDX
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
prnewswire.com
SNDX
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
globenewswire.com
SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
SNDX